TQB2934 injection for systemic light chain amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1/2 program gives subcutaneous TQB2934 to adults with systemic light chain (AL) amyloidosis in a dose-finding Phase 1b portion followed by a Phase 2 expansion. Phase 1b (13–21 subjects) will characterize safety, pharmacokinetics, pharmacodynamics, immunogenicity, and determine a recommended Phase 2 dose. Phase 2 plans to enroll about 49 subjects with relapsed/refractory disease previously treated with daratumumab and bortezomib to see if the hematologic complete response rate is higher than historical controls. The primary endpoint is hematologic complete response rate and the total planned enrollment is approximately 70 subjects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The subjects voluntarily joined this study, signed the informed consent form, and exhibited good compliance;
* Aged 18 to 80 years old, with an Eastern Cooperative Oncology Group (ECOG) score of 0 to 2, and an expected survival of more than 12 weeks;
* Systemic light chain amyloidosis with diagnostic records (i.e., primary light chain amyloidosis);
* Presence of measurable lesions;
* At least one organ involved;
* Have previously received at least one line of systemic treatment, and recurred and progressed after the remission of the last line treatment;
* N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≤ 8500 ng/L;
* The corresponding organ function conforms to the protocol requirements;
* Women of childbearing age should agree to use contraception during the study period and for 6 months after its completion; they must have a negative serum pregnancy test within 7 days before enrollment in the study and must be non-lactating subjects; men should agree to use contraception during the study period and for 6 months after its completion.

Exclusion Criteria:

* Diagnosed with other types of amyloidosis, active plasma cell leukemia, active multiple myeloma, etc.
* Have received allogeneic hematopoietic stem cell transplantation within 1 year prior to the first dose, or have received autologous hematopoietic stem cell transplantation within 12 weeks prior to the first dose;
* Previously received treatment with drugs targeting the same target;
* Within 4 weeks prior to the first dose, the patient has received a cumulative dose of dexamethasone \>160 mg or an equivalent dose of other glucocorticoids, or within 3 weeks prior to the first dose, the patient has received targeted therapy, cytotoxic drugs, or any antibody therapy, or within 2 weeks prior to the first dose, the patient has received proteasome inhibitor therapy or radiotherapy, or within 1 week prior to the first dose, the patient has received immunomodulator therapy;
* Those who have received treatment with traditional Chinese patent medicines and simple preparations with clear anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks before the first administration;
* Those who have received attenuated live vaccine within 4 weeks before the first dose or plan to receive attenuated live vaccine during the study period;
* Individuals with a history of severe allergies of unknown cause, or known allergies to monoclonal antibody drugs or exogenous human immunoglobulins, or known allergies to the excipients in injectable TQB2934 or pharmaceutical preparations;
* Having had or currently suffering from other malignant tumors within 3 years before the first medication;
* Unresolved toxic reactions above Common Terminology Criteria (CTC) AE Grade 1 caused by any previous treatment;
* Those who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the study treatment period within 4 weeks before the first dose of medication;
* Arterial/venous thromboembolic events occurred within 6 months before the first dose;
* Individuals with a history of abuse of psychotropic drugs who are unable to quit or who have mental disorders; or intractable seizures that require treatment;
* Those with unsatisfactory blood pressure control;
* Patients with poorly controlled diabetes;
* Patients who have active or uncontrolled severe bacterial, viral, or systemic fungal infections (≥CTC AE Grade 2 infections) within 4 weeks before the first dose of medication;
* Patients with hepatitis or decompensated liver cirrhosis (Child-Pugh Class B or C);
* Individuals with active tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment, or clinically symptomatic active pneumonia;
* Those who have experienced asthma within 2 years before the first medication or currently suffer from asthma or chronic obstructive pulmonary disease;
* Individuals with significant cardiovascular diseases;
* Individuals with a history of immune deficiency, or active autoimmune diseases requiring systemic immunosuppressive therapy, etc.
* Exclude subjects with organ failure unrelated to systemic light-chain (AL) amyloidosis;
* Subjects deemed unsuitable for enrollment by the researchers.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University First Hospital
  Beijing, Beijing Municipality, China Not yet recruiting
• Southwest Hospital, Third Military Medical University (Army Medical University)
  Chongqing, Chongqing Municipality, China Not yet recruiting
• Fujian Medical University Union Hospital
  Fuzhou, Fujian, China Not yet recruiting
• The First Affiliated Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Not yet recruiting
• Guangzhou First Municipal People's Hospital
  Guangzhou, Guangdong, China Not yet recruiting

Study contacts

• Study coordinator: Jin Lu, Doctor
• Email: jinllu@sina.com
• Phone: 13311491805

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose BCMA/CD3 (CM336) treatment for newly diagnosed AL (light-chain) amyloidosis

  This trial will try a low-dose BCMA/CD3 bispecific antibody (CM336) in adults newly diagnosed with systemic light-chain (AL) amyloidosis to see if it is safe and lowers abnormal light-chain levels and helps organ function.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07151690

• TQF3250 Capsules in overweight and obese adults with limited weight loss from lifestyle changes

  This phase 1b study tests whether TQF3250 capsules are safe and tolerable, and whether they show preliminary signs of benefit, in adults with overweight or obesity who have not achieved enough weight loss with simple lifestyle changes.

  Recruiting at 6 sites Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 9 other locations · NCT07798284

• TQF3250 capsules for adults with type 2 diabetes and overweight/obesity

  A small, early-phase study will test the safety and how the body handles different doses of TQF3250 pills in adults with type 2 diabetes who are overweight or obese.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuzhou, Fujian and 11 other locations · NCT07747857

• GPC3-targeted ADC for advanced solid tumors

  This early-phase trial tests a Glypican-3 targeted antibody-drug conjugate (TQB6426) in adults with advanced cancers to see if it is safe and tolerable and to explore potential anti-tumor activity.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 7 other locations · NCT07730190

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

• TQB3126 in Breast Cancer: Safety, PK, and Early Efficacy in Adults

  This study tests TQB3126 to see if it is safe and tolerable and to get early signals of benefit in adults with breast cancer who have progressed after prior therapy.

  Recruiting at 6 sites Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Guangzhou, Guangdong and 5 other locations · NCT07697443

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.